Edgewise Therapeutics (EWTX)

Healthcare · Biotechnology
$39.06 -0.43% on the day Market cap $3.9B 52-week range $14.25 to $48.51 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Edgewise Therapeutics's free cash flow was negative in fiscal 2025, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

F

Five factors scored 1 to 9 from EWTX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation3
Profitability0
Financial health9

Results from SEC filings

Fiscal years, from Edgewise Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue—————
Net income-$43M-$68M-$100M-$134M-$168M
Free cash flow-$34M-$58M-$98M-$110M-$144M
EPS (diluted)-$1.14-$1.26-$1.57-$1.45-$1.63
Operating margin—————

Superinvestors who own EWTX

From each investor's latest 13F filing (what a 13F shows). 1 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Cliff Asness
AQR Capital Management
Added $749,8690.0%Q2 2026

Insider buying

Open-market purchases by Edgewise Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

DateInsiderSharesPriceValue
Nov 11, 2025 Jonathan C Fox
10,700$18.64$199,448

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when EWTX trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are Edgewise Therapeutics insiders buying the stock?

1 open-market insider purchase of EWTX in the last 12 months, from SEC Form 4 filings.

Which superinvestors own Edgewise Therapeutics?

1 of the superinvestors Investingly tracks hold EWTX in their latest 13F, including Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.